{"id":704257,"date":"2024-06-26T16:52:01","date_gmt":"2024-06-26T16:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=704257"},"modified":"2024-06-26T16:52:01","modified_gmt":"2024-06-26T16:52:01","slug":"mice-model-market-worth-22-billion-marketsandmarkets","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/mice-model-market-worth-22-billion-marketsandmarkets_704257.html","title":{"rendered":"Mice Model Market Worth $2.2 billion | MarketsandMarkets\u2122"},"content":{"rendered":"
\n
\"Mice<\/a><\/div>\n
\n
North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising rate of cancer and other chronic diseases has contributed to growth of the mice model market.<\/div>\n<\/div>\n<\/div>\n
Mice Model Market in terms of revenue was estimated to be worth $1.5 billion in 2024 and is poised to reach $2.2 billion by 2029, growing at a CAGR of 8.1% from 2024 to 2029 according to a new report by MarketsandMarkets\u2122<\/div>\n

Mice Model Market<\/a><\/strong> in terms of revenue was estimated to be worth $1.5 billion in 2024 and is poised to reach $2.2 billion by 2029, growing at a CAGR of 8.1% from 2024 to 2029 according to a new report by MarketsandMarkets™. The rise in chronic diseases, such as cancer, diabetes, and cardiovascular disorders, and growing need for reliable and predictive animal models to facilitate drug discovery and development are the major driving factors of the mice model market. However, the presence of alternative research models, and recent guidelines of U.S.FDA on restriction animal models can hamper market growth.<\/p>\n

Download an Illustrative overview: https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=1308<\/a><\/strong><\/p>\n

The inbred mice segment accounted for the largest share by model type in the mice model market in 2023.<\/strong><\/p>\n

By model type, the mice model market has been further categorized into inbred mice, genetically engineered mice, hybrid\/congenic mice, and outbred mice. Inbred mice accounted for the largest share of the mice model market in 2023. The pivotal role played by genetic uniformity provides consistency and reproducibility, making them ideal for studying complex traits and diseases, contributes significantly to the expansion of this segment within the mice model market.<\/p>\n

The CRISPR\/Cas9 segment is expected to grow at a higher rate during the forecast period.<\/strong><\/p>\n

Based on technology, the mice model market has been segmented into CRISPR\/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies. In 2023, the CRISPR\/Cas9 segment accounted for the largest share of the mice model market is expected to grow at a higher growth rate during the forecast period of 2024-2029. CRISPR technology offers a cost-effective solution for generating genetically modified mice compared to traditional methods such as embryonic stem cell-based targeting.<\/p>\n

The oncology segment accounted for the largest share of the therapeutic area segment in the mice model market in 2023.<\/strong><\/p>\n

Based on therapeutic area, the mice model market is segmented into oncology, neurology, metabolic diseases, immunology, cardiovascular diseases, and other diseases. In 2023, oncology accounted for the largest share of the mice model market. The expansion of the oncology mice model market is fueled by a surge in research funding dedicated to the advancement of personalized drug products for cancer treatment. For instance, the National Cancer Institute (NCI) allocated an estimated USD 6,467 million from its research budget, covering diverse disease areas such as AIDS, brain & CNS, and cancer.<\/p>\n

The North America region accounted for the largest share of the mice model market in 2023.<\/strong><\/p>\n

The mice model market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. The North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising rate of cancer and other chronic diseases has contributed to growth of the mice model market.<\/p>\n

Request Sample Pages: <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=1308<\/a><\/strong><\/p>\n

Mice Model Market<\/strong> Dynamics:<\/strong><\/p>\n

Drivers:<\/strong><\/p>\n

    \n
  1. High adoption of mice models in preclinical studies<\/li>\n
  2. Increasing demand for mouse clinical trials (MCTs)<\/li>\n
  3. Growing preference for personalized medicine in oncology<\/li>\n
  4. Advancements in genetic engineering<\/li>\n<\/ol>\n

    Restraints:<\/strong><\/p>\n

      \n
    1. Introduction of 3D printed models<\/li>\n
    2. Ethical concerns and regulatory restrictions<\/li>\n<\/ol>\n

      Opportunities:<\/strong><\/p>\n

        \n
      1. Low Utilization of CRISPR in biomedical research<\/li>\n
      2. Rising demand for disease-specific models<\/li>\n<\/ol>\n

        Challenge:<\/strong><\/p>\n

          \n
        1. Development of alternative animal testing methods<\/li>\n
        2. Genetic & Phenotypic variability<\/li>\n<\/ol>\n

          Key Market Players of <\/strong>Mice Model Industry<\/strong>:<\/strong><\/p>\n

          Key players in the mice model market Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), GemPharmatech (China), Cyagen (US), Shanghai Model Organisms Center, Inc. (China), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan), Ozgene Pty Ltd. (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Harbour BioMed (China), Marshall BioResources (US), genOway (France), Vivo Bio Tech Ltd. (India), ingenious targeting laboratory (US), Janvier Labs (France), Applied StemCell (US), Creative Animodel (US), JOINN Laboratories Co., Ltd. (China), Creative Biolabs (US), Crescendo Biologics (UK), Aragen Life Sciences (India), and PolyGene (Switzerland).<\/p>\n

          The primary interviews conducted for this report can be categorized as follows:<\/strong><\/p>\n